25513-92-2

Basic information

• Product Name: ETHYL 3-METHYLPYRAZINE-2-CARBOXYLATE
• Synonyms: ETHYL 3-METHYLPYRAZINE-2-CARBOXYLATE;3-Methylpyrazine-2-carboxylate;ethyl 3-methylpyrazine-2-carboxylateChemical Formula: C8H10N2O2 Exact Mass: 166.07 Molecular Weight: 166.18 m/z: 166.07 (100.0%), 167.08 (8.8%) Elemental Analysis: C, 57.82: H, 6.07: N, 16.86: O, 19.2
• CAS NO: 25513-92-2
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.18
• Mol File: 25513-92-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 51.5-52.5 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• Boiling Point: 239.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.133±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.52±0.10(Predicted)
• CAS DataBase Reference: ETHYL 3-METHYLPYRAZINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-METHYLPYRAZINE-2-CARBOXYLATE(25513-92-2)
• EPA Substance Registry System: ETHYL 3-METHYLPYRAZINE-2-CARBOXYLATE(25513-92-2)

Safety Data

• Hazardous Substances Data: 25513-92-2(Hazardous Substances Data)

Usage

Uses

Ethyl 3-methylpyrazine-2-carboxylate is used as a reactant in the preparation of pyrazines, piperazinones, and quinoxalines.

Upstream product

• 64-17-5 ethanol 
• 41110-28-5 3-methylpyrazine-2-carboxylic acid 
• 95239-03-5 tert-butyl 2-(4-ethoxy-4-oxobut-2-en-2-yl)diazene-1-carboxylate 
• 107-15-3 ethylenediamine 
• 94127-05-6 ethyl 3-[(aminocarbonyl)diazenyl]but-2-enoate 

Downstream Products

• 1383919-14-9 3-[2-chloro-4-methanesulfonyl-3-(3-methyl-4,5-dihydro-isoxazol-5-yl)-phenylmethanesulfonylmethyl]-pyrazine-2-carboxylic acid methyl ester 
• 1383919-13-8 3-[2-chloro-4-methanesulfonyl-3-(3-methyl-4,5-dihydro-isoxazol-5-yl)benzylsulfanylmethyl]-pyrazine-2-carboxylic acid methyl ester 

Relevant articles and documents

Straightforward access to pyrazines, piperazinones, and quinoxalines by reactions of 1,2-diaza-1,3-butadienes with 1,2-diamines under solution, solvent-free, or solid-phase conditions

The preparation of tetrahydropyrazines, dihydropyrazines, pyrazines, piperazinones, and quinoxalines by 1,4-addition of 1,2-diamines to 1,2-diaza-1,3-butadienes bearing carboxylate, carboxamide, or phosphorylated groups at the terminal carbon and subseque

Dipeptidyl peptidase-IV inhibitors

The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R1 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

Cofactor inhibition of thymidylate synthetase. Tetrahydrofolic acid analogs.

-